Introduction
============

COPD is a major cause of mortality and morbidity.[@b1-copd-11-1015] Extrapulmonary alterations, notably cardiac complications such as cor pulmonale, can be frequently observed in patients with COPD. In addition, coronary artery disease and heart failure may play important roles in mortality and morbidity in patients with COPD.[@b2-copd-11-1015] Cardiovascular complications might not only be related to CODP itself but could also be due to a chronic systemic inflammatory condition, in which heart and lungs are differentially involved.[@b3-copd-11-1015] Interestingly, changes in left ventricle function and structure such as left ventricular hypertrophy (LVH), diastolic dysfunction, and reduction in cardiac chambers and stroke volume have been described but might not be exclusively due to COPD.[@b4-copd-11-1015]--[@b6-copd-11-1015] The lower preload caused by hyperinflation may be responsible for reduced left ventricular (LV) and right ventricular (RV) dimensions[@b4-copd-11-1015],[@b5-copd-11-1015] yet, a causal link between COPD and increased LV mass (LVM)[@b6-copd-11-1015] has not been clearly established. Notably, these authors demonstrated a higher (30% versus 20% in controls) prevalence of LVH in normoxemic, normotensive patients with COPD, unrelated to forced expiratory volume in 1 second (FEV~1~). In that study, relative wall thickness (RWT) value (an index of LV geometry) was similar between patients with COPD and controls.[@b6-copd-11-1015] Chronic inflammation or pronounced activation of the renin--angiotensin--aldosterone system rather than airway obstruction could play major yet unclear roles.

It is worth noting that an echocardiographic-detected LVH is a strong predictor of cardiovascular events, especially when combined with concentric remodeling revealed by an increased RWT.[@b7-copd-11-1015],[@b8-copd-11-1015] Therefore, the assessment of LV geometry in patients with COPD could have relevant clinical impacts in terms of improving risk stratification for future cardiovascular events and augmenting prognosis. Thus far, this issue remains poorly investigated.

With the aim of characterizing cardiac remodeling in COPD, we selected patients from all Global Initiative for Chronic Obstructive Lung Disease (GOLD) classes, without history of cardiovascular disease, in order to exclude any confounding factor. The aims of the present work were twofold: 1) to evaluate the influence of different degrees of airway obstruction and lung hyperinflation on cardiac structures by analyzing both the right and the left ventricles. By evaluating LVM and RWT, we wanted to quantify LV remodeling and the prevalence of LVH in COPD and 2) to study the relationship between LV remodeling and morbidity of a COPD cohort.

Materials and methods
=====================

Study population
----------------

This study conforms to the Declaration of Helsinki and was approved by the Institutional Medical Ethics Committee of the University of Parma. All participants provided signed informed consent before recruitment (Protocol number 41361).

From 2008 to April 2015, we screened inpatients and outpatients of both sexes, affected by COPD ranging from mild-to-severe airflow obstruction, who were referred to the Lung Unit of the University Hospital of Parma. We selected only patients with COPD without previous diagnosis of cardiac disorders such as coronary artery disease, heart failure, significant valvular dysfunction, cardiomyopathies, chronic atrial fibrillation, or pacemaker and left bundle branch blocks. Patients with systemic arterial hypertension higher than stage I and insulin-dependent diabetes were also excluded. Patients with COPD were diagnosed and classified according to the GOLD criteria. As control group, we recruited sex- and age-matched healthy subjects. Participants underwent spirometry and conventional and Doppler tissue echocardiography (DTE). Patients with COPD also underwent computed tomography (CT) scan.

Clinical examination
--------------------

After recording their personal and parental medical history, study subjects underwent a physical examination and 12-lead resting electrocardiography; their blood pressure (BP) was determined in triplicate at 2-minute intervals (OMRON 705 IT, Omron, Kyoto, Japan). A normal office BP was defined as ≤140/90 mmHg.[@b9-copd-11-1015] Body mass index (BMI) was calculated in kg/m^2^.

Pulmonary function testing
--------------------------

Pulmonary function was measured by a flow-sensing spirometer connected to a computer for data analysis (Vmax 22 and 6200, Sensor Medics, Yorba Linda, CA, USA). Functional residual capacity was measured by body plethysmography (Vmax 22 and 6200, Sensor Medics). Total lung capacity (TLC) was calculated as the sum of functional residual capacity and linked inspiratory capacity. Residual volume was obtained by subtracting vital capacity (VC) from TLC. At least three measurements were taken for each spirometry and lung volume variable to ensure reproducibility. Forced vital capacity (FVC), FEV~1~, RV, and TLC were recorded and expressed as percent of predicted value. FEV~1~/FVC and residual volume/TLC were also recorded and expressed as a ratio.

Conventional and Doppler tissue echocardiography
------------------------------------------------

M-mode, two-dimensional, and Doppler echocardiography were performed by one ultrasonography-experienced cardiologist (GP), using commercially available, multihertz sector, 2--4 MHz probe-equipped machines (Acuson Aspen, Siemens, Mountain View, CA, USA; Vivid S5, GE Healthcare, Wauwatosa, WI, USA). The examination was feasible for screening cardiac parameters in all the patients with COPD, despite concerns that echocardiography windows might be poor.

The interventricular septal (SWT) and posterior wall (PWT) thicknesses, systolic (ESD) and diastolic (EDD) LV diameters, absolute LVM, and indexed-to-body-surface-area (LVM/BSA) were calculated as previously described.[@b10-copd-11-1015],[@b11-copd-11-1015] LVH was defined as an LVM/BSA of \>95 g/m^2^ in women and \>115 g/m^2^ in men.[@b12-copd-11-1015] RWT was calculated as (SWT + PWT)/EDD, using the 0.42 cutoff to define eccentric (≤0.42) or concentric (≥0.42) remodeling.[@b12-copd-11-1015] Simpson's biplane rule-based end-diastolic (EDV) and systolic (ESV) volumes and ejection fraction (EF) were calculated, while fractional shortening (FS) was calculated as (\[EDV − ESV\]/EDV) ×100.

The RV cavity was measured from the long-axis parasternal view to extract the transversal dimension at end-diastole and end-systole. Using the apical four-chamber view, the longitudinal axis (as the distance between the apex of the right ventricle and the center of the tricuspid ring) and the maximal transversal diameter, in the basal one-third of the RV inflow, were measured at the end-diastole.[@b12-copd-11-1015] Pulmonary pressure was calculated directly by sampling the tricuspid insufficiency and indirectly by the acceleration time on pulmonary flow.

Mitral and tricuspidal inflow patterns were analyzed from apical four-chamber view and E- and A-wave, and their ratios were considered as peak flow velocity and time velocity integral, to evaluate the conventional diastolic function of both ventricles. From the same projection, DTE analysis was performed at the lateral site and posteroseptum of mitral annulus and lateral site of tricuspidal annulus to assess myocardial systolic (S) and diastolic (E′, A′) waves of LV and RV. All measurements were usually made in triplicate during different heart cycles, as previously reported.[@b11-copd-11-1015],[@b13-copd-11-1015]

CT scan
-------

Forty-three patients with COPD have been recently studied with 6- and 64-detector row CT scanners (Siemens Medical Solutions, Forchheim, Germany). All whole-lung CT scans were acquired during one deep inspiratory breath-hold without the use of any contrast medium. Both scanners were daily calibrated on air to allow reliable measurements and comparison between examinations. Standard 6-detector row CT scanner parameters were as follows: 120 kV, effective 120 mAs, individual detector collimation 1 mm, gantry rotation time of 0.5 second, and pitch 1.25. The 64-detector row CT scanner parameters were as follows: 120 kV, effective 100 mAs, individual detector collimation 0.6 mm, gantry rotation time of 0.5 second, and pitch 1.

CT images data were reconstructed at 1-mm-thick sections with a reconstruction increment of 1 mm and a sharp kernel (B70f). They were transferred to a personal computer running MevisPULMO software (version 1.4, Fraunhofer MEVIS, Bremen, Germany) and analyzed for quantitative emphysema assessment by one operator (NS). A 3×3 kernel-based axial Gauss smoothing was applied to minimize the noise in sharp kernel images. For the whole lung, emphysema extent was defined as percentage of lung voxels ≤−950 Hounsfield units.[@b14-copd-11-1015]

Statistical analysis
--------------------

Data are expressed as mean ± standard deviation (SD) or median (interquartile range) depending on the normality of data, assessed by using the Kolmogorov--Smirnov test. Consequently, controls and patients with COPD were compared for each variable using parametric or nonparametric univariate statistics (Student's *t*-test or Mann--Whitney test). Pearson correlations were performed to analyze the associations between variables of lung function (such as GOLD class, spirometry data, and emphysema score) and cardiac chamber size.

Multiple regression analysis was used to analyze the relationship between COPD disease and the echocardiographic-based variables (LVM, RWT, and LV EDD), with age, heart rate (HR), BMI, and systolic BP or pulmonary pressure, respectively, for LV or RV parameters as the covariates. Smoking habits, FEV~1~, and FEV~1~/FVC were not included in the analysis as collinear with the presence of COPD disease (*R*-values \>0.5 and variance inflation factor in multivariate models \>2).

To test if RWT was predictive of the severity of COPD disease in patients with COPD, receiver operating characteristic (ROC) curve was done reporting the area under curve (AUC) value as general diagnostic tool, and the flex point, ie, where the sum of sensitivity and specificity reached a maximum, was used to divide the patients with COPD into two groups.

Hospitalizations for patients with COPD were considered as 1) overall number of hospitalizations for COPD and/or CV events normalized for observation time, rounding the number as integer in 10 years and 2) time elapsing from the start of the study and the first hospitalization. In the first case, because of the distribution of hospitalization, an over-dispersed Poisson regression model was performed. In the second case, a Cox regression model was applied. In both cases, the categorical variable RWT ≤ cutoff point and \>cutoff point was used.

A two-tailed *P*-value \<0.05 was always considered as significant. SPSS 22.0 (IBM Corporation, Armonk, NY, USA) was used for all the statistical analysis.

Results
=======

Patients' characteristics
-------------------------

We scrutinized 56 COPD inpatients and outpatients. Seven patients with negative cardiovascular history were excluded during enrollment because of a mild valvular and/or dilative heart disease as detected by echocardiography. A total of 49 patients (45--85 years old) were finally enrolled. In 43 patients, CT scans were available. We screened 36 healthy volunteers without previous history of respiratory, cardiovascular, and metabolic disorders as the control group.

The clinical data of patients with COPD and of their controls are presented in [Table 1](#t1-copd-11-1015){ref-type="table"}. Patients were slightly older than controls, but both groups matched for sex and anthropometric parameters such as BMI and BSA. Systolic and diastolic BPs of the two groups were superimposable, but HR was higher in patients than in controls. Smoking habits and medical history of hypertension were greater in COPD (*P*\<0.001 and *P*\<0.05, respectively). No significant difference was observed in the history of diabetes mellitus ([Table 1](#t1-copd-11-1015){ref-type="table"}).

Pulmonary function values are listed in [Table 2](#t2-copd-11-1015){ref-type="table"}. All the GOLD-4 classes were homogenously (21%, 35%, 29%, and 15%) represented. The emphysema score was 18%±13% ranging from 1% to 53%. A total of 33 (68%) patients with COPD received inhaled β2 agonist agents, 26 (53%) received inhaled steroids, and 17 (35%) received inhaled muscarinic antagonists. The majority of hypertensive individuals were treated with a monotherapy of antihypertensive agents, while only six patients with COPD received a combination therapy (four COPD and one control with β-blockers, 18 COPD and three controls with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and five COPD and one control with calcium antagonists).

During follow-up (42.2 \[SD: 20.7\] months), seven patients with COPD died and 16 were hospitalized once or more for respiratory or cardiac complications (only two because of cardiovascular events).

Echocardiography
----------------

Patients with COPD, as compared with controls, exhibited a significant decrease of LV chamber size as assessed by EDD and EDV, which was associated with a significant increase in SWT and a mild, nonsignificant increase in PWT. Therefore, RWT was markedly higher in patients, suggesting that concentric remodeling occurs in COPD ([Table 3](#t3-copd-11-1015){ref-type="table"}). The absolute and indexed LVM were similar in the two groups as was the percentage of patients with positive ECHO criteria for LVH.

LV systolic functions, assessed by FS and EF, were similar between the two groups, but stroke volume was lower in COPD versus controls ([Table 4](#t4-copd-11-1015){ref-type="table"}). The mitral inflow pattern showed significant reduction of the E/A ratios in patients with COPD, but no significant differences in systolic and diastolic functions were detected by DTE between the two groups ([Table 4](#t4-copd-11-1015){ref-type="table"}).

[Table 5](#t5-copd-11-1015){ref-type="table"} reports the results of RV assessment. A mild but nonsignificant increase in ventricular dimensions was observed in patients with COPD. The tricuspidal E-wave and the myocardial E′, E′/A′ ratios and S′-wave, all assessed as time--velocity integral, were reduced, suggesting impairments of both systolic and diastolic functions. Pulmonary pressure estimated by tricuspidal insufficiency was increased, and the acceleration time of pulmonary ejection was reduced in patients with COPD ([Table 5](#t5-copd-11-1015){ref-type="table"}).

After univariate analysis, RWT was strongly correlated with FEV~1~, FEV~1~/FVC, GOLD class, and emphysema scores. EDD and EDV showed significant correlations only with the emphysema score. Finally, SWT correlated with FEV~1~, GOLD class, and CT score but not with FEV~1~/FVC ([Table 6](#t6-copd-11-1015){ref-type="table"}).

Multiple regression analysis was performed to test the association between LV echocardiographic-derived parameters (RWT, SWT, EDD, and EDV) as outcomes and age, sex, BMI, systolic BP, HR, and the clinical condition (controls or COPD) as predictors ([Table 7](#t7-copd-11-1015){ref-type="table"}). Only RWT was associated with COPD. All echocardiographic variables -- but not SWT -- were related to HR. Sex, as expected,[@b15-copd-11-1015] influenced LV structure. No association was found between the RV parameters and COPD.

ROC curve analysis showed that RWT, with a cutoff point of 0.40, predicted the severity of the disease with an 83% specificity and a 56% sensitivity (AUC =0.69, 95% CI =0.59--0.81). Patients with COPD with RWT \>0.40 versus patients with RWT ≤0.40 (RWT_CAT variable) showed a significant reduction of FEV~1~/FVC (*P*=0.017) and a significant increase in emphysema score (*P*=0.033), whereas FEV~1~ and residual volume/TLC were not significantly different.

Univariate statistics showed that RWT was associated with a higher number of hospitalizations (*P*=0.034). However, in the multivariate Poisson regression model including age, systolic BP, HR, body surface area, and FEV~1~/FVC, we did not detect significant differences, with FEV~1~/FVC (exp\[B\] =0.87 \[0.79--0.95\], *P*=0.003) and age (exp\[B\] =1.11 \[1.01--1.21\], *P*=0.023) being the only significantly different variables.

Data from the previous analysis were confirmed when the time between enrollment and first hospitalization was considered. Specifically, in a Cox regression model with the same covariates, age (HR =1.08 \[1.00--1.17\], *P*=0.047) and FEV~1~/FVC (HR =0.88 \[0.80--0.96\], *P*=0.005) were the only significantly different variables.

Finally, overall patient survival was not considered in the statistical analysis because only seven patients died during our study.

Discussion
==========

The main finding of our study is that COPD is associated with LV structural changes characterized by a decrease in EDD and EDV as well as an alteration of ventricular geometry, notably concentric remodeling. Other authors who used echocardiographic techniques and nuclear magnetic resonance,[@b5-copd-11-1015],[@b16-copd-11-1015] reported the relationship between COPD and decreased LV size, but this is the first report that provides evidence of direct links between pulmonary function, CT score, and LV geometry.

In our study, patients with COPD had an increased RWT compared with controls; on average, the former showed RWT values \>0.42, which was considered as the cutoff point beyond which concentric remodeling was diagnosed.[@b17-copd-11-1015] In addition, a more severe degree of respiratory disease was associated with a greater increase of concentric remodeling, as indicated by the significant relationship between LV geometry and GOLD class, spirometry parameters, and CT emphysema score. Furthermore, the outcome of a multivariate statistical analysis including LV echocardiographic-derived parameters (RWT, SWT, EDD, and EDV) as dependent variables and age, sex, BMI, BP, HR and the clinical COPD condition as predictors showed that only RWT was independently related to COPD, whereas no relationship was observed with the other echocardiographic parameters.

Our study does not confirm the LVH in COPD reported by Anderson et al.[@b6-copd-11-1015] The absolute and indexed LVM was unchanged in our patients as compared with controls. It is noteworthy that our results are in agreement with those previously reported by echocardiography[@b18-copd-11-1015] with the highly sophisticated technique -- nuclear magnetic resonance.[@b4-copd-11-1015] Differences in the selection criteria may explain these discrepancies. For example, unlike the study by Anderson et al,[@b6-copd-11-1015] our patients belonged to all GOLD classes. Moreover, our population included only patients with grade 1 hypertension, treated mostly by monotherapy. We excluded hypertensive patients affected by grades 2 and 3 hypertension. A greater systolic BP in COPD versus controls, as demonstrated by the ambulatory and 24-hour monitoring and the number of antihypertensive-per-treated patients with COPD (median =2), has also been reported by Anderson et al.[@b6-copd-11-1015] In addition, the age differences in our cohort were low (mean difference\~3 years), albeit weakly statistically significant. By contrast, in the study by Anderson et al,[@b6-copd-11-1015] the COPD group was, on average, 10 years older than the controls. This \~10-year age difference between the two groups may be critical because population studies report that age is a strong determinant of LVM, independent of height, weight, and sex, both in childhood and in adults.[@b19-copd-11-1015],[@b20-copd-11-1015] In turn, the previously observed differences in LVM between COPD and controls could be mainly related to the different ages of the two groups.

Although we did not find any difference in LVH between the two groups, our patients with COPD exhibited a significant increase in RWT as compared with controls. This is crucial to stratify cardiovascular risk in the general population, as a concentric LV remodeling (normal LV mass with increased RWT) is a well-known negative prognostic factor.[@b7-copd-11-1015],[@b17-copd-11-1015]

As previously demonstrated by Barr et al,[@b16-copd-11-1015] the extent of emphysema on CT scanning was linearly related to cardiac dimensions expressed by EDD and EDV: a greater magnitude of emphysema corresponds to a greater reduction in LV cavity size. Several explanations have been proposed to explain the relationship between COPD and microcardia. First, there is a lower preload in left cardiac chambers mediated by an intrathoracic hypovolemia and a decrease of the pulmonary vascular bed caused by dynamic hyperinflation.[@b4-copd-11-1015] This mechanism may explain not only the reductions in LV diameters and volumes but also the lower stroke volumes[@b16-copd-11-1015] and the supposed LV diastolic dysfunction found at the transmitral Doppler analysis.[@b21-copd-11-1015] Indeed, the inflow pattern is not only an index of ventricular relaxation and compliance, but it is also influenced by others variables such as the preload and the HR. A lower preload can mimic an impaired LV relaxation in normal functioning heart.[@b22-copd-11-1015] More sophisticated techniques, such as DTE, which analyzes the contraction and relaxation velocities directly on the myocardium, are less influenced by ventricular loads and provide more sensitive indexes of diastolic function.[@b22-copd-11-1015]--[@b24-copd-11-1015] In our study, the E/A ratio from the mitral inflow pattern was significantly reduced in COPD, but the myocardial S- and E′-waves were preserved, excluding an impairment in the LV systolic and diastolic function.

A leftward shift of the interventricular septum consequent to the increased right ventricular afterload could cause a decrease in LV cavity size.[@b21-copd-11-1015],[@b25-copd-11-1015] However, this premise is not entirely convincing because, in our study, the configuration of this wall did not differ between the two groups, and we did not find any significant RV enlargement despite the significant increase in pulmonary artery pressure. Our findings are in agreement with previous studies[@b4-copd-11-1015],[@b5-copd-11-1015] that found even smaller RV secondary to the hyperinflation and subsequent lower preload to both heart chambers. In addition, patients with COPD had impaired RV systolic and diastolic functions, as demonstrated by the significant reductions of S- and E′-waves, which were significantly related only to pulmonary artery pressure but not to CT score or FEV~1~/FVC. In summary, we report structural and functional cardiac changes in COPD, but only RWT was independently related to the COPD condition (after multivariate analysis).

To verify if RWT predicted the severity of the disease, we divided the COPD cohort into two groups according to the ROC curves analysis, and we observed that patients with RWT \>0.40 were sicker, with more pronounced reduction in FEV~1~/FVC and more increase in CT score. The prognostic role of RWT was also assessed in relation to respiratory and cardiac hospitalizations: only after the univariate statistics, but not after multivariate Poisson analysis, cardiac geometry was significantly related to this event, with age and FEV~1~/FVC being the only strong predictors. These analyses did not show LV geometry as morbidity predictor, confirming the role of age and clinical variables; however, we speculate that, in a larger series of patients, this structural cardiac index may prove a useful marker of hospitalization risk. During the follow-up, seven deaths occurred, but, owing to the limited number of fatal events, overall patient survival was not considered in the statistical analysis. However, the comparisons between survivors and nonsurvivors revealed that RWT was significantly higher (0.52 versus 0.42, *P*=0.014) in nonsurvivors, suggesting its potential prognostic value as mortality predictor, which has to be confirmed in the future with a greater number of fatal events.

Limitations and strengths
=========================

The first limitation of our study is the limited number of patients. We must emphasize that all enrolled subjects were thoroughly screened and selected for the absence of any significant comorbidities with effects on the structure and heart function. The average age of the two groups (\>60 years) is the one in which it is difficult to encounter subjects free of cardiovascular disease, hypertension, or diabetes.

The strength of the present study is that a single expert investigator recruited and appraised patients and performed all echocardiographies, thus reducing analytical variability.

Conclusion
==========

We demonstrated that significant alterations -- typified by a concentric remodeling -- exist in the LV geometry of patients with COPD. LV geometry, compared with LVM, is a little-known marker of cardiovascular risk. Such structural LV modifications are not associated with an increased LVM or with LV systolic and diastolic dysfunctions. RWT appears to be the only cardiac parameter independently related to COPD and could help identify those patients at greatest risk of cardiac complications. Further studies are warranted to ascertain whether LV geometry is related to morbidity and mortality in COPD.
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###### 

Anthropometric and clinical data

  Parameter                                   COPD (n=49)   Controls (n=36)   *P*-value
  ------------------------------------------- ------------- ----------------- -----------
  Age (years)                                 66.3±9.1      62.7±6.5          \<0.05
  Male/female (%)                             76/24         69/31             ns
  Height (cm)                                 1.7±0.1       1.7±0.1           ns
  Weight (kg)                                 72±13         75±10             ns
  BMI (kg/m^2^)                               25.3±4.0      25.8±3.0          ns
  BSA (m^2^)                                  1.8±0.2       1.9±0.2           ns
  SBP (mmHg)                                  132±12        131±11            ns
  DBP (mmHg)                                  82±8          83±5              ns
  HR (beats-per-minute)                       77±13         67±8              \<0.001
  Smokers (active and non) (%)                90            31                \<0.001
  Arterial hypertension history I stage (%)   43            19                \<0.05
  Diabetes mellitus (%)                       6             0                 ns
  No hospitalization (%)                      32/49 (66)    0                 
  1 hospitalization (%)                       8 (16.7)      --                
  \>1 hospitalization (%)                     8 (16.7)      --                

**Note:** Data are mean ± standard deviation or percentage.

**Abbreviations:** BMI, body mass index; BSA, body surface area; DBP, diastolic blood pressure; HR, heart rate; ns, nonsignificant; SBP, systolic blood pressure.

###### 

Lung functional characteristics

  Spirometry and pletismography   COPD (n=49)   Controls (n=36)   *P*-value
  ------------------------------- ------------- ----------------- -----------
  FEV~1~ (L)                      1.6±0.8       3.1±0.6           \<0.0001
  FEV~1~ (%)                      57±25         106±13            \<0.0001
  FVC (L)                         3.0±1.0       4.0±0.8           \<0.0001
  FEV~1~/FVC                      49±12         75±5              \<0.0001
  Residual volume (L)             3.4±1.3       2.9±1.0           ns
  Residual volume (%)             149±55        126±46            ns
  TLC (L)                         6.9±1.5       7.2±1.4           ns
  TLC (%)                         115±23        115±20            ns
  RV/TLC                          48±13         41±16             0.05

**Note:** Data mean ± standard deviation or percentage.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; ns, nonsignificant; RV, right ventricular; TLC, total lung capacity.

###### 

Cardiac structural characteristics assessed by echocardiography

  LV morphologic parameters       COPD (n=49)   Controls (n=36)   *P*-value
  ------------------------------- ------------- ----------------- -----------
  End-diastolic diameter (mm)     45±6          48±4              \<0.01
  End-systolic diameter (mm)      28±6          29±5              ns
  End-diastolic volume (mL)       90±27         101±18            \<0.05
  End-systolic volume (mL)        29±12         32±11             ns
  Septal thickness (mm)           9.8±1.6       9.0±1.4           \<0.05
  Posterior wall thickness (mm)   9.4±1.4       8.9±1.9           ns
  RWT                             0.44±0.09     0.37±0.05         \<0.001
  LVM (g)                         183±54        191±50            ns
  LVM/BSA (g/m^2^)                99±24         100±22            ns
  LV hypertrophy (%)              36            44                ns

**Note:** Data mean ± standard deviation or percentage.

**Abbreviations:** BSA, body surface area; LV, left ventricular; LVM, left ventricular mass; RWT, relative wall thickness.

###### 

Left ventricular functional characteristics assessed by echocardiography

  Parameter              COPD (n=49)   Controls (n=36)   *P*-value
  ---------------------- ------------- ----------------- -----------
  FS (%)                 40±12         42±6              ns
  EF (%)                 69±6          68±7              ns
  SV (mL)                61±17         69±11             \<0.05
  Mitral E pv (cm/s)     53.6±13.6     58.3±13.2         ns
  Mitral E tvi (cm)      8.8±2.6       10.2±2.0          \<0.05
  Mitral A pv (cm/s)     69.8±12.3     67.1±11.8         ns
  Mitral A tvi (cm)      8.4±1.9       8.4±2.5           ns
  Mitral E/A pv (cm/s)   0.8±0.2       0.9±0.1           ns
  Mitral E/A tvi (cm)    1.1±0.3       1.3±0.4           \<0.01
  DTE S pv (cm/s)        10.7±2.2      10.6±2.1          ns
  DTE S tvi (cm)         2.1±0.8       2.1±0.4           ns
  DTE E′ pv (cm/s)       10.0±2.6      9.8±2.4           ns
  DTE E′ tvi (cm)        1.1±0.3       1.1±0.4           ns
  DTE A′ pv (cm/s)       13.9±3.1      13.9±2.6          ns
  DTE A′ tvi (cm)        1.2±0.3       1.2±0.3           ns
  DTE E′/A′ pv           0.9±0.9       0.8±0.3           ns
  DTE E′/A′ tvi          0.9±0.3       0.9±0.4           ns

**Notes:** Data mean ± standard deviation. Values from DTE analysis are the mean of septal and lateral walls.

**Abbreviations:** A′, end-diastolic myocardial wave; DTE, Doppler tissue echocardiography; E′, proto-diastolic myocardial wave; EF, ejection fraction; FS, fraction of shortening; pv, peak velocity; S, systolic myocardial wave; SV, stroke volume; tvi, time velocity integral.

###### 

Right ventricular characteristics assessed by echocardiography

  Right ventricle               COPD (n=49)   Controls (n=36)   *P*-value
  ----------------------------- ------------- ----------------- -----------
  End-diastolic diameter (mm)   35.2±5.2      33.4±4.1          ns
  End-systolic diameter (mm)    25.2±4.7      24.1±3.9          ns
  Trasversal diameter (mm)      36.8±6.5      36.3±5.1          ns
  Longitudinal diameter (mm)    65.7±8.7      65.2±7.2          ns
  DTE S pv (cm/s)               15.4±4.2      16.1±4.2          ns
  DTE S tvi (cm)                2.9±0.9       3.2±0.7           \<0.05
  Tricuspid E pv (cm/s)         40.9±8.9      40.9±8.7          ns
  Tricuspid E tvi (cm)          6.6±2.2       7.7±2.1           \<0.05
  Tricuspid A pv (cm/s)         42.5±9.5      40.1±7.1          ns
  Tricuspid A tvi (cm)          5.0±1.5       5.1±1.4           ns
  DTE E′ pv (cm/s)              13.1±4.0      14.6±3.7          ns
  DTE E′ tvi (cm)               2.1±0.8       2.5±0.7           0.01
  DTE A′ pv (cm/s)              18.3±4.3      18.5±4.2          ns
  DTE A′ tvi (cm)               1.9±0.5       1.9±0.5           ns
  Tricuspid E/A pv              1.0±0.2       1.0±0.3           ns
  Tricuspid E/A tvi             1.4±0.5       1.6±0.5           ns
  DTE E′/A′ pv                  0.7±0.2       0.8±0.2           ns
  DTE E′/A′ tvi                 1.1±0.4       1.3±0.3           \<0.05
  Pulmonary pressure (mmHg)     30.9±8.2      25.8±3.4          \<0.01
  AT on pulmonary flow (ms)     119±29        144±22            \<0.001

**Note:** Data are mean ± standard deviation.

**Abbreviations:** A′, end-diastolic myocardial wave; AT, acceleration time; DTE, Doppler tissue echocardiography; E′, proto-diastolic myocardial wave; pv, peak velocity; tvi, time velocity integral; S, systolic myocardial wave.

###### 

Correlations between lung function, CT score, and cardiac chamber size values

  Variable     EDD     EDV      RWT     SWT                               
  ------------ ------- -------- ------- -------- ------- -------- ------- --------
  FEV~1~       0.10    ns       0.16    ns       −0.35   \<0.05   −0.32   \<0.05
  FEV~1~/FVC   0.17    ns       0.18    ns       −0.34   \<0.05   −0.22   ns
  GOLD class   −0.15   ns       −0.21   ns       0.36    \<0.01   0.33    \<0.05
  CT score     −0.36   \<0.01   −0.28   \<0.05   0.41    \<0.01   0.28    \<0.05

**Abbreviations:** CT, computed tomography; EDD, left ventricular end-diastolic diameter; EDV, left ventricular end-diastolic volume; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ns, nonsignificant; RWT, relative wall thickness; SWT, septal wall thickness.

###### 

Multiple regression analysis of the predicting relationship of COPD status with the echocardiographic-based variables, ie, RWT, EDV, EDD, and SWT

  Variable   RWT (*R*^2^=0.30)   EDD (*R*^2^=0.35)   EDV (*R*^2^=0.41)   SWT (*R*^2^=0.34)                                                  
  ---------- ------------------- ------------------- ------------------- ------------------- --------------- ------------- ---------------- -------------
  COPD       0.039 (0.017)       **0.027**           −1.83 (1.17)        0.12                −6.08 (4.77)    0.21          0.53 (0.32)      0.11
  Age        0.001 (0.001)       0.74                −0.034 (0.077)      0.66                −0.31 (0.31)    0.33          0.018 (0.021)    0.40
  Sex        −0.057 (0.021)      **0.009**           −2.63 (1.44)        0.072               −17.05 (5.89)   **0.005**     −1.65 (0.40)     \<**0.001**
  SBP        −0.001 (0.001)      0.062               0.086 (0.050)       0.090               0.46 (0.20)     **0.021**     −0.035 (0.014)   **0.012**
  BMI        −0.005 (0.002)      0.059               0.39 (0.17)         **0.024**           1.14 (0.66)     0.091         0.038 (0.046)    0.72
  HR         0.002 (0.001)       **0.011**           −0.16 (0.05)        **0.003**           −0.76 (0.20)    \<**0.001**   0.010 (0.014)    0.82

**Notes:** Age, HR, BMI, and SBP were considered as the covariates. Only RWT was significantly associated with COPD status. Data with statistical significance are shown in bold.

**Abbreviations:** BMI, body mass index; EDD, end-diastolic diameter; EDV, end-diastolic volume; HR, heart rate; RWT, relative wall thickness; SE, standard error; SBP, systolic blood pressure; SWT, septal wall thickness.
